Life Sciences Cos. See Jump In Securities Suits, Dechert Finds
The life sciences industry was hit hard with securities fraud allegations in 2014, with investor class actions brought against pharmaceutical, biotechnology and medical companies nearly doubling from the year prior, according...To view the full article, register now.
Already a subscriber? Click here to view full article